Ignite Creation Date:
2025-12-24 @ 10:19 PM
Ignite Modification Date:
2026-02-27 @ 8:48 AM
Study NCT ID:
NCT03875235
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-10
First Post:
2019-03-13
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-04-16
Start Date Type:
ACTUAL
Primary Completion Date:
2021-08-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2019-03-13
First Submit QC Date:
None
Study First Post Date:
2019-03-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-08-10
Results First Submit QC Date:
None
Results First Post Date:
2023-04-13
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-30
Last Update Post Date:
2025-10-10
Last Update Post Date Type:
ESTIMATED